Myopia
Conditions
Brief summary
The objective of the study is to compare the clinical performance of silicone hydrogel daily disposable contact lenses, conventional hydrogel daily disposable contact lenses and silicone hydrogel monthly replacement contact lenses.
Interventions
Silicone Hydrogel Daily Disposable Contact Lenses
DEVICEnelfilcon A contact lens
Conventional Hydrogel Daily Disposable Contact Lenses
Silicone Hydrogel Monthly Replacement Contact Lenses
Sponsors
Visioncare Research Ltd.
Johnson & Johnson Vision Care, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 39 Years
Healthy volunteers
No
Inclusion criteria
* Be no less than 18 and no more than 39 years of age. * Sign Written Informed Consent and investigator to record this on Case Report Form (See separate document). * Be willing and able to adhere to the instructions set out in the protocol. * Own a cell phone and be willing to receive text messages during the day. * Be an existing successful daily wear soft contact lens. For the purposes of this study this means wearing lenses for at least 6 hours per day, 5 days per week for the last month. * No extended wear in the last 3 months. * Subjective refraction must result in a vertexed spherical contact lens prescription between -1.00 and -6.00D. * Have refractive astigmatism less than or equal to 1.00D in both eyes. * Achieve visual acuity of 6/9 (20/30) or better in each eye. * Require a visual correction in both eyes (no monofit or monovision allowed). * Does not require presbyopic correction (i.e. Not using any presbyopic correction and measured add power of less than +1.00D). * Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having: * No amblyopia. * No evidence of lid abnormality or infection (including blepharitis/meibomitis). * No conjunctival abnormality or infection. * No clinically significant slit lamp findings (i.e. stromal edema, vascularization, infiltrates or abnormal opacities). * No other active ocular disease.
Exclusion criteria
* Requires concurrent ocular medication. * Clinically significant (Grade 3 or 4) corneal stromal haze, corneal vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear. * Clinically significant corneal staining (Grade 3 in more than one corneal region per eye). * Requires presbyopic correction (i.e. Not using any presbyopic correction and measured add power of less than +1.00D). * Has had refractive surgery. * Has had eye injury/surgery within 8 weeks immediately prior to enrolment for this study. * Abnormal lacrimal secretions. * Pre-existing ocular irritation that would preclude contact lens fitting. * Keratoconus or other corneal irregularity. * PMMA(polymethyl methacrylate), hybrid or RGP(rigid gas permeable) lens wear in the previous 8 weeks. Does not require presbyopic correction (i.e. Not using any presbyopic correction and measured add power of less than +1.00D). * Any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear. * Diabetic. * Infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV (Human immunodeficiency virus)). * History of chronic eye disease (e.g. glaucoma or ARMD (age related macular degeneration)). * Pregnancy, lactating or planning a pregnancy at the time of enrolment. * Participation in any concurrent clinical trial or in last 30 days.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Comfort Narafilcon B v. Nelfilcon A | After 1 week | Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. |
| Signs of Limbal Hyperemia Narafilcon B v. Nelfilcon A | After 1 Week | Redness scale of 0 to 4, where 0=None, 4=Severe redness |
| Subjective Rating of Overall Comfort Narafilcon B v. Lotrafilcon B | After 4 Weeks | Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. |
| Signs of Limbal Hyperemia Narafilcon B v. Lotrafilcon B | After 4 Weeks | Redness scale of 0 to 4, where 0=None, and 4=Severe. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Signs of Inferior Corneal Staining Narafilcon B v. Lotrafilcon B | After 4 Weeks | Scale of 0 to 3, where 0=none and 3=severe staining. |
| Subjective Rating of Overall Ease of Lens Handling Narafilcon B v. Lotrafilcon B | After 4 Weeks | Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. |
| Signs of Inferior Corneal Staining Narafilcon B v. Nelfilcon A | After 1 Week | Standard scale of 0 to 3 where 0=None, 3=Severe staining |
| Subjective Rating of Initial Comfort Narafilcon B v. Lotrafilcon B | After 4 Weeks | Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort, 5=excellent comfort. |
| Subjective Rating of End of Day Comfort Narafilcon B v. Lotrafilcon B | After 4 Weeks | Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort |
| Subjective Rating of Overall Ease of Lens Handling Narafilcon B v Nelfilcon A | After 1 Week | Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. |
| Subjective Rating of End of Day Comfort Narafilcon B v. Nelfilcon A | After 1 Week | Scale of 1 to 5, where 1=Poor comfort and 5=Excellent comfort |
| Subjective Rating of Initial Comfort Narafilcon B v. Nelfilcon A | After 1 Week | Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Narafilcon B 4 Weeks lenses worn daily on a daily disposable/replacement schedule, for 4 weeks | 149 |
| Nelfilcon A 1 Week lenses worn daily on a daily disposable/replacement schedule, for 1 week | 150 |
| Lotrafilcon B 4 Weeks lenses worn daily on a 1-month replacement schedule, for 4 weeks | 153 |
| Total | 452 |
Baseline characteristics
| Characteristic | Narafilcon B 4 Weeks | Nelfilcon A 1 Week | Lotrafilcon B 4 Weeks | Total |
|---|---|---|---|---|
| Age, Continuous | 27.9 years STANDARD_DEVIATION 6.4 | 27.6 years STANDARD_DEVIATION 6 | 28 years STANDARD_DEVIATION 6.2 | 27.8 years STANDARD_DEVIATION 6.2 |
| Region of Enrollment United States | 149 participants | 150 participants | 153 participants | 452 participants |
| Sex: Female, Male Female | 112 Participants | 104 Participants | 112 Participants | 328 Participants |
| Sex: Female, Male Male | 37 Participants | 46 Participants | 41 Participants | 124 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 149 | 0 / 150 | 0 / 153 |
| serious Total, serious adverse events | 0 / 149 | 0 / 150 | 0 / 153 |
Outcome results
Primary
Overall Comfort Narafilcon B v. Nelfilcon A
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Time frame: After 1 week
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Narafilcon B | Overall Comfort Narafilcon B v. Nelfilcon A | 68.32 units on a scale | Standard Deviation 22.82 |
| Nelfilcon A | Overall Comfort Narafilcon B v. Nelfilcon A | 53.75 units on a scale | Standard Deviation 23.71 |
Primary
Signs of Limbal Hyperemia Narafilcon B v. Lotrafilcon B
Redness scale of 0 to 4, where 0=None, and 4=Severe.
Time frame: After 4 Weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Narafilcon B | Signs of Limbal Hyperemia Narafilcon B v. Lotrafilcon B | 0.44 units on a scale | Standard Deviation 0.47 |
| Nelfilcon A | Signs of Limbal Hyperemia Narafilcon B v. Lotrafilcon B | 0.68 units on a scale | Standard Deviation 0.61 |
Primary
Signs of Limbal Hyperemia Narafilcon B v. Nelfilcon A
Redness scale of 0 to 4, where 0=None, 4=Severe redness
Time frame: After 1 Week
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Narafilcon B | Signs of Limbal Hyperemia Narafilcon B v. Nelfilcon A | 0.53 Units on a scale | Standard Deviation 0.5 |
| Nelfilcon A | Signs of Limbal Hyperemia Narafilcon B v. Nelfilcon A | 0.61 Units on a scale | Standard Deviation 0.51 |
Primary
Subjective Rating of Overall Comfort Narafilcon B v. Lotrafilcon B
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Time frame: After 4 Weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Narafilcon B | Subjective Rating of Overall Comfort Narafilcon B v. Lotrafilcon B | 66.43 units on a scale | Standard Deviation 23.37 |
| Nelfilcon A | Subjective Rating of Overall Comfort Narafilcon B v. Lotrafilcon B | 53.91 units on a scale | Standard Deviation 23.72 |
Secondary
Signs of Inferior Corneal Staining Narafilcon B v. Lotrafilcon B
Scale of 0 to 3, where 0=none and 3=severe staining.
Time frame: After 4 Weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Narafilcon B | Signs of Inferior Corneal Staining Narafilcon B v. Lotrafilcon B | 0.14 units on a scale | Standard Deviation 0.41 |
| Nelfilcon A | Signs of Inferior Corneal Staining Narafilcon B v. Lotrafilcon B | 0.34 units on a scale | Standard Deviation 0.6 |
Secondary
Signs of Inferior Corneal Staining Narafilcon B v. Nelfilcon A
Standard scale of 0 to 3 where 0=None, 3=Severe staining
Time frame: After 1 Week
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Narafilcon B | Signs of Inferior Corneal Staining Narafilcon B v. Nelfilcon A | 0.13 units on a scale | Standard Deviation 0.36 |
| Nelfilcon A | Signs of Inferior Corneal Staining Narafilcon B v. Nelfilcon A | 0.31 units on a scale | Standard Deviation 0.57 |
Secondary
Subjective Rating of End of Day Comfort Narafilcon B v. Lotrafilcon B
Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort
Time frame: After 4 Weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Narafilcon B | Subjective Rating of End of Day Comfort Narafilcon B v. Lotrafilcon B | 3.55 units on a scale | Standard Error 0.11 |
| Nelfilcon A | Subjective Rating of End of Day Comfort Narafilcon B v. Lotrafilcon B | 2.95 units on a scale | Standard Error 0.11 |
Secondary
Subjective Rating of End of Day Comfort Narafilcon B v. Nelfilcon A
Scale of 1 to 5, where 1=Poor comfort and 5=Excellent comfort
Time frame: After 1 Week
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Narafilcon B | Subjective Rating of End of Day Comfort Narafilcon B v. Nelfilcon A | 3.69 units on a scale | Standard Error 0.11 |
| Nelfilcon A | Subjective Rating of End of Day Comfort Narafilcon B v. Nelfilcon A | 2.81 units on a scale | Standard Error 0.11 |
Secondary
Subjective Rating of Initial Comfort Narafilcon B v. Lotrafilcon B
Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort, 5=excellent comfort.
Time frame: After 4 Weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Narafilcon B | Subjective Rating of Initial Comfort Narafilcon B v. Lotrafilcon B | 4.25 units on a scale | Standard Error 0.1 |
| Nelfilcon A | Subjective Rating of Initial Comfort Narafilcon B v. Lotrafilcon B | 3.79 units on a scale | Standard Error 0.09 |
Secondary
Subjective Rating of Initial Comfort Narafilcon B v. Nelfilcon A
Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort.
Time frame: After 1 Week
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Narafilcon B | Subjective Rating of Initial Comfort Narafilcon B v. Nelfilcon A | 4.10 units on a scale | Standard Error 0.13 |
| Nelfilcon A | Subjective Rating of Initial Comfort Narafilcon B v. Nelfilcon A | 3.92 units on a scale | Standard Error 10 |
Secondary
Subjective Rating of Overall Ease of Lens Handling Narafilcon B v. Lotrafilcon B
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Time frame: After 4 Weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Narafilcon B | Subjective Rating of Overall Ease of Lens Handling Narafilcon B v. Lotrafilcon B | 62.58 units on a scale | Standard Deviation 22.79 |
| Nelfilcon A | Subjective Rating of Overall Ease of Lens Handling Narafilcon B v. Lotrafilcon B | 55.50 units on a scale | Standard Deviation 22.47 |
Secondary
Subjective Rating of Overall Ease of Lens Handling Narafilcon B v Nelfilcon A
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Time frame: After 1 Week
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Narafilcon B | Subjective Rating of Overall Ease of Lens Handling Narafilcon B v Nelfilcon A | 64.05 units on a scale | Standard Deviation 22.35 |
| Nelfilcon A | Subjective Rating of Overall Ease of Lens Handling Narafilcon B v Nelfilcon A | 60.76 units on a scale | Standard Deviation 22.03 |